BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/6/2019 11:50:46 AM | Browse: 965 | Download: 1093
 |
Received |
|
2019-04-13 05:39 |
|
Peer-Review Started |
|
2019-04-15 06:19 |
|
To Make the First Decision |
|
2019-05-28 02:59 |
|
Return for Revision |
|
2019-06-03 08:50 |
|
Revised |
|
2019-06-16 12:18 |
|
Second Decision |
|
2019-06-20 04:57 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-06-27 06:31 |
|
Articles in Press |
|
2019-06-27 06:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-07-08 04:42 |
|
Typeset the Manuscript |
|
2019-08-05 05:59 |
|
Publish the Manuscript Online |
|
2019-08-06 11:50 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
HER2 heterogeneity is a poor prognosticator for HER2 positive gastric cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, Kohei Shitara, Reo Sato, Tetsuo Akimoto and Takahiro Kinoshita |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Takeshi Kuwata, MD, PhD, Doctor, Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa 277-8577, Japan. tkuwata@east.ncc.go.jp |
| Key Words |
Human epidermal growth factor receptor 2; Heterogeneity; Trastuzumab; Gastric cancer; ; |
| Core Tip |
Although intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity was reported as important predictor to trastuzumab-based chemotherapy for HER2 positive breast cancer, the clinical significance of HER2 heterogeneity for gastric cancer had been unclear. We defined intratumoral HER2 heterogeneity as biopsy specimens which were taken from two or more different portion of the tumor showed different immunohistochemistry HER2 positivity, and HER2 heterogeneity based on this definition was pivotal poor predictor of tumor shrinkage and poor prognosticator. Thus, intratumoral HER2 heterogeneity should be included to assessment of HER2 positivity. |
| Publish Date |
2019-08-06 11:50 |
| Citation |
Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2 positive gastric cancer. World J Clin Cases 2019; 7(15):1964-1977 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i15/1964.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i15.1964 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
